VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2021 | T-cell lineage mixed chimerism as a prognostic factor in acute leukemia & MDS after allo-HSCT

Vipul Sheth, PhD, Fred Hutchinson Cancer Research Center, Seattle, USA, discusses the findings of a single center retrospective study of T-cell lineage mixed chimerism as a prognostic factor in acute leukemias and myelodysplastic syndromes (MDS). T-cell depletion, in particular with alemtuzumab, reduces the risk of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) with unrelated donor peripheral stem cell grafts. However, it has also been associated with an increased occurrence of mixed T-cell chimerism and subsequent relapse. Dr Sheth describes the findings of a study which compared the long-term outcomes of 106 patients with T-cell mixed chimerism to 111 patients with complete chimerism. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter